Viking Therapeutics, Inc.
VKTXAPI behind this page
VKTX Q1 2026 request
Playground key active
/api/financials?ticker=VKTX&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Research & Development (Q) | — | — | — |
Show — breakouts |
|||
| Research & Development | 150,150 | 41,391 | +262.8% |
| General & Administrative (Q) | — | — | — |
Show — breakouts |
|||
| General & Administrative | 13,975 | 14,078 | -0.7% |
| Operating Expenses (Q) | — | — | — |
Show — breakouts |
|||
| Operating Expenses | 164,125 | 55,469 | +195.9% |
| Operating Income (Q) | — | — | — |
Show — breakouts |
|||
| Operating Income | -164,125 | -55,469 | -195.9% |
| Interest Income Expense Nonoperating Net (Q) | — | — | — |
Show — breakouts |
|||
| Interest Income Expense Nonoperating Net | 5,800 | 9,864 | -41.2% |
| Other Non-Operating Income (Expense) (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Operating Income (Expense) | 5,800 | 9,840 | -41.1% |
| Net Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Retained Earnings | -158,325 | -45,629 | -247.0% |
Show — breakouts |
|||
| Net Income | -158,325 | -45,629 | -247.0% |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,250 | 563 | -322.0% |
Show — breakouts |
|||
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -1,250 | 563 | -322.0% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 16 | 9 | +77.8% |
Show — breakouts |
|||
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | 16 | 9 | +77.8% |
| Comprehensive Income (Q) | — | — | — |
Show — breakouts |
|||
| Comprehensive Income | -159,559 | -45,057 | -254.1% |
| EPS (Basic) (Q) | — | — | — |
Show — breakouts |
|||
| EPS (Basic) | -1.37 | -0.41 | -234.1% |
| EPS (Diluted) (Q) | — | — | — |
Show — breakouts |
|||
| EPS (Diluted) | -1.37 | -0.41 | -234.1% |
| Wtd Avg Shares (Basic) (Q) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Basic) | 115,568 | 112,069 | +3.1% |
| Wtd Avg Shares (Diluted) (Q) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Diluted) | 115,568 | 112,069 | +3.1% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show — breakouts |
|||
| Foreign Currency Transaction Gain Loss Before Tax | 16,000 | 9,000 | +77.8% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash & Cash Equivalents | 118,116 | — | — |
| Available For Sale Securities Debt Securities Current (Q) | — | — | — |
Show — breakouts |
|||
| Available For Sale Securities Debt Securities Current | 484,848 | — | — |
| Prepaid Clinical Trial And Preclinical Study Costs (Q) | — | — | — |
Show — breakouts |
|||
| Prepaid Clinical Trial And Preclinical Study Costs | 4,021 | — | — |
| Prepaid Expenses & Other Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Prepaid Expenses & Other Current Assets | 1,224 | — | — |
| Total Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Assets | 608,209 | — | — |
| Non-Current Assets | |||
| Deposits Assets Noncurrent (Q) | — | — | — |
Show — breakouts |
|||
| Deposits Assets Noncurrent | 33 | — | — |
| Total Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Assets | 608,242 | — | — |
| Current Liabilities | |||
| Accounts Payable (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Payable | 67,183 | — | — |
| Other Accrued Liabilities Current (Q) | — | — | — |
Show — breakouts |
|||
| Other Accrued Liabilities Current | 39,142 | — | — |
| Total Current Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Liabilities | 106,325 | — | — |
| Non-Current Liabilities | |||
| Total Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities | 106,325 | — | — |
| Stockholders' Equity | |||
| Common Stock (Q) | — | — | — |
Show — breakouts |
|||
| Common Stock | 1 | — | — |
| Additional Paid In Capital Common Stock (Q) | — | — | — |
Show — breakouts |
|||
| Additional Paid In Capital Common Stock | 1,508,643 | — | — |
| Retained Earnings (Q) | — | — | — |
Show — breakouts |
|||
| Retained Earnings | -1,005,871 | — | — |
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax (Q) | — | — | — |
Show — breakouts |
|||
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -856 | — | — |
| Total Stockholders' Equity (Q) | — | — | — |
Show — breakouts |
|||
| Total Stockholders' Equity | 501,917 | — | — |
| Total Liabilities & Equity (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities & Equity | 608,242 | — | — |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income (Q) | — | — | — |
Show — breakouts |
|||
| Net Income | -158,325 | -45,629 | -247.0% |
| Accretion Amortization Of Discounts And Premiums Investments (Q) | — | — | — |
Show — breakouts |
|||
| Accretion Amortization Of Discounts And Premiums Investments | -1,293 | -3,133 | +58.7% |
| Stock-Based Compensation (Q) | — | — | — |
Show — breakouts |
|||
| Stock-Based Compensation | 10,337 | 11,348 | -8.9% |
Show Award Date breakouts |
|||
| January 2023 [Member] · Performance Based Restricted Stock Units [Member] | 187,000 | — | — |
| January 2025 [Member] · Performance Based Restricted Stock Units [Member] | -94,000 | — | — |
| January 2026 [Member] · Performance Based Restricted Stock Units [Member] | 2 | — | — |
| January Two Thousand Twenty Four [Member] · Performance Based Restricted Stock Units [Member] | 400,000 | — | — |
Show Award Type breakouts |
|||
| Employee Stock Option | 5,345 | 4,248 | +25.8% |
| Employee Stock Purchase Plan [Member] | 138 | 140 | -1.4% |
| Performance Based Restricted Stock Units [Member] | 39,000 | — | — |
| Restricted stock and restricted stock units [Member] | 4,854 | 6,960 | -30.3% |
Show Income Statement Location breakouts |
|||
| General And Administrative Expense | 7,080 | 7,367 | -3.9% |
| Research And Development Expense | 3,257 | 3,981 | -18.2% |
| Operating Lease Right Of Use Asset Amortization Expense (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Right Of Use Asset Amortization Expense | 85 | 111 | -23.4% |
| Operating Leases Interest Expense (Q) | — | — | — |
Show — breakouts |
|||
| Operating Leases Interest Expense | 1 | 10 | -90.0% |
| Change in Prepaid & Other Assets (Q) | — | — | — |
Show — breakouts |
|||
| Change in Prepaid & Other Assets | 4,628 | -9,554 | +148.4% |
| Change In Accrued Interest Relating To Marketable Securities Held As Investments (Q) | — | — | — |
Show — breakouts |
|||
| Change In Accrued Interest Relating To Marketable Securities Held As Investments | 936 | 2,470 | -62.1% |
| Change in Accounts Payable (Q) | — | — | — |
Show — breakouts |
|||
| Change in Accounts Payable | 13,931 | -2,110 | +760.2% |
| Increase Decrease In Accrued Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Accrued Liabilities | 15,863 | -5,739 | +376.4% |
| Increase Decrease In Operating Lease Liability (Q) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Operating Lease Liability | -139 | -129 | -7.8% |
| Net Cash from Operations (Q) | — | — | — |
Show — breakouts |
|||
| Net Cash from Operations | -113,976 | -52,331 | -117.8% |
| Investing Activities | |||
| Payments To Acquire Investments (Q) | — | — | — |
Show — breakouts |
|||
| Payments To Acquire Investments | -72,437 | -232,614 | +68.9% |
| Proceeds From Sale Maturity And Collections Of Investments (Q) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale Maturity And Collections Of Investments | 126,626 | 295,859 | -57.2% |
| Net Cash from Investing (Q) | — | — | — |
Show — breakouts |
|||
| Net Cash from Investing | 54,189 | 63,245 | -14.3% |
| Unpaid Deferred Initial Public Offering And Other Financing Costs (Q) | — | — | — |
Show — breakouts |
|||
| Unpaid Deferred Initial Public Offering And Other Financing Costs | 50 | 50 | 0.0% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options (Q) | — | — | — |
Show — breakouts |
|||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 450 | 349 | +28.9% |
| Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees (Q) | — | — | — |
Show — breakouts |
|||
| Proceeds From Issuance Of At The Market Equity Offering Sales Agreement Net Of Fees | 11,627 | — | — |
| Net Cash from Financing (Q) | — | — | — |
Show — breakouts |
|||
| Net Cash from Financing | 12,077 | 349 | +3360.5% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect (Q) | — | — | — |
Show — breakouts |
|||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -47,710 | 11,263 | -523.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations (Q) | — | — | — |
Show — breakouts |
|||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 118,116 | 37,940 | +211.3% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations (Q) | — | — | — |
Show — breakouts |
|||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 16 | 1 | +1500.0% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.